These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28068325)

  • 1. TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation.
    Li J; Xi Y; Li W; McCarthy RL; Stratton SA; Zou W; Li W; Dent SY; Jain AK; Barton MC
    Oncogene; 2017 May; 36(21):2991-3001. PubMed ID: 28068325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
    Wu J; Crowe DL
    Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
    Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
    Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
    Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
    Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
    Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
    Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
    Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
    Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
    Gautam N; Kaur M; Kaur S
    J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.
    Crawford NT; McIntyre AJ; McCormick A; D'Costa ZC; Buckley NE; Mullan PB
    Oncogene; 2019 Aug; 38(31):5971-5986. PubMed ID: 31253870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
    Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
    Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
    Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
    Mu W; Starmer J; Yee D; Magnuson T
    Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of polycomb targets predicts breast cancer prognosis.
    Jene-Sanz A; Váraljai R; Vilkova AV; Khramtsova GF; Khramtsov AI; Olopade OI; Lopez-Bigas N; Benevolenskaya EV
    Mol Cell Biol; 2013 Oct; 33(19):3951-61. PubMed ID: 23918806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Dissection of Oligomerization by the TRIM28 Tripartite Motif and the Interaction with Members of the Krab-ZFP Family.
    Sun Y; Keown JR; Black MM; Raclot C; Demarais N; Trono D; Turelli P; Goldstone DC
    J Mol Biol; 2019 Jun; 431(14):2511-2527. PubMed ID: 31078555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.